

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) A method for increasing GC-C Receptor activity, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 2.-3. (canceled)
4. (original) A method for increasing intestinal motility, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 5.-7. (canceled)
8. (currently amended) The method of claim [[7]] 20 wherein the gastrointestinal disorder is selected from the group consisting of: constipation, a gastrointestinal motility disorder, irritable bowel syndrome, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, and colonic pseudo-obstruction.
- 9.-11. (canceled)
12. (Currently Amended) The method of ~~any of claims 1-11~~ claim 1 further comprising administering guanylin or a biologically active variant or fragment thereof.
13. (original) A pharmaceutical composition comprising a chymotrypsin inhibitor and a pharmaceutically acceptable carrier.

14. (original) The composition of claim 10 further comprising guanylin or a biologically active variant or fragment thereof.
15. (original) The composition of claim 14 further comprising a GC-C Receptor agonist.
16. (currently amended) The method of ~~any of claims 1-11~~ claim 1 further comprising administering a GC-C Receptor agonist.
17. (canceled)
18. (new) The method of claim 1 wherein the disorder is congestive heart failure.
19. (new) The method of claim 1 wherein the disorder is prostatic hyperplasia.
20. (new) The method of claim 1 wherein the disorder is a gastrointestinal disorder.
21. (new) The method of claim 1 wherein the disorder is obesity.